Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00036257 · ClinicalTrials.gov registry record · Phase 1
Dose-Escalating and Safety Study of CP-461 in Patients With Chronic Lymphocytic Leukemia
A Phase 1 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT00036257 is a Phase 1 study that has completed, run by Astellas Pharma. The registered enrollment target is 15 participants.
The verdict
NCT00036257, a Phase 1 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purposes of this study are to determine a maximum tolerated dose and to evaluate the safety and efficacy of CP-461 in patients with Chronic Lymphocytic Leukemia.
Interventions
- DRUG CP-461
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2002-03 |
| Est. Completion | 2003-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00036257
The ClinicalTrials.gov registry entry for NCT00036257 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CP-461 is the first listed.
NCT00036257 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00036257 about?
NCT00036257 is a clinical study titled "Dose-Escalating and Safety Study of CP-461 in Patients With Chronic Lymphocytic Leukemia". The purposes of this study are to determine a maximum tolerated dose and to evaluate the safety and efficacy of CP-461 in patients with Chronic Lymphocytic Leukemia.
What is the current status of trial NCT00036257?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2002-03. Estimated completion is 2003-04.
What interventions are being tested in trial NCT00036257?
The interventions under investigation include: CP-461 (DRUG).
Who is sponsoring clinical trial NCT00036257?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.